Quote · The Prof G Pod with Scott Galloway
Why People Are Losing Faith in Healthcare
Where this was said
Beyond Obesity: Inflammation, Addiction, and Cancer
At 14:05 · chapter starts 10:10
What began as a diabetes drug keeps revealing new capabilities. Ricks walks through the cascade: inflammation reduction (GLP-1s appear to be powerful anti-inflammatories, relevant to arthritis, asthma, psoriasis), and then the stranger, harder-to-explain behavioral effects. Patients in trials spontaneously drank less alcohol, gambled less, and shopped less online — without being asked or prompted. The mechanism, Ricks theorizes, is that alcohol is chemically close to glucose, and the same brain signaling that reduces sugar cravings quiets alcohol desire too. Critically, he pushes back on the 'joy kill switch' narrative: people don't lose pleasure, they just find less appetite for excess. Lilly is now running Phase 3 trials on brenepatide for alcohol use disorder. On pain: retatrutide, the triple-acting drug expected to launch next year, showed the most powerful knee pain reduction ever recorded pharmacologically — a finding with enormous implications given the scale of chronic pain in America. Cancer connections remain observational but are striking: people on GLP-1s for 5–6 years appear to have lower rates of colorectal and breast cancer.
Lilly's triple-acting GLP-1 drug retatrutide, expected for launch next year, produced the most powerful pharmacological pain reduction ever recorded for knee arthritis. The finding was unexpected and points to GLP-1s as potential game-changers for America's massive chronic pain burden.
Lilly's triple-acting retatrutide demonstrated the most powerful pain-reduction ever recorded pharmacologically for knee arthritis in clinical studies.
Obesity is described as a 'nodal health condition' connected to more than 200 chronic diseases, making GLP-1 treatment uniquely high-leverage.
Patients in GLP-1 trials spontaneously reduced alcohol intake, gambling, and even online shopping without being prompted. Lilly is now pursuing a Phase 3 drug — brenepatide — specifically for alcohol use disorder, as the mechanism appears to quiet hedonic urges broadly.
Lilly is pursuing brenepatide in Phase 3 trials specifically for alcohol use disorder, after observational data showed GLP-1 users spontaneously drink less.
US drug pricing is systemically regressive: the largest institutional buyers get the lowest prices, while uninsured or underinsured individuals pay the most. Lilly created LillyDirect to let consumers buy directly at institutional prices, cutting Zepbound's cost by 60% to $399/month.
